What was recalled
This page synthesizes the AAFCO novel ingredient approval pathway framework around commercial pet food alternative protein and emerging-category ingredients. The pathway is the same Ingredient Definitions Committee (IDC) process used for all new ingredients (covered in our AAFCO ingredient definition process page), but novel-ingredient cases face additional regulatory scrutiny through FDA-CVM safety review depth, public comment intensity, and industry adoption-pace pressure. Novel ingredients for AAFCO purposes are ingredients that do not have established regulatory history in the US food and feed supply, including: alternative protein (insect protein, microbial single-cell protein, precision-fermented animal protein, cultured meat, mycoprotein, algae-derived protein), novel processing aids (enzyme preparations from new microbial sources, fermentation-derived flavor compounds), and novel functional ingredients (probiotic strain-specific preparations, postbiotic preparations from novel fermentation processes).
The regulatory friction unique to novel ingredients includes: (i) FDA-CVM safety review depth — novel ingredients without established food/feed history require extensive safety data including manufacturing process safety, allergenicity assessment, and toxicological data; the FDA-CVM ex-officio role in IDC review means novel-ingredient petitions face de-facto federal safety review without formal FDA regulatory action; (ii) industry adoption pace pressure — alternative protein sponsors (insect protein companies, cultured meat companies, precision fermentation companies) often have venture-funded commercial timelines that conflict with the 5-7 year AAFCO process, producing pressure to enter commercial pet food at tentative-definition status or to pursue FDA-CVM no-questions-letters or Generally Recognized as Safe (GRAS) self-affirmation as alternative regulatory pathways; (iii) public comment intensity — novel-ingredient definitions attract more public comment than routine ingredient definitions, with veterinary nutrition academics, sustainability advocates, and consumer protection groups all engaging.
The black soldier fly larvae (BSF, Hermetia illucens) timeline is the most-documented novel-ingredient AAFCO approval case. Industry petition activity began approximately 2014-2016 as insect protein companies (Enterra Feed in Canada, Protix in Netherlands, Insect Pure, Jiminy's, and others) pursued US commercial pet food entry. Preliminary tentative definition was assigned mid-2010s, tentative definition status followed several years later, and adult dog food official definition status was approved in 2021. The cat food official definition followed in 2024, three years after the dog food definition. The total 5-7 year timeline is consistent with the broader AAFCO IDC novel-ingredient pattern. Cricket protein (Acheta domesticus), mealworm (Tenebrio molitor), microbial single-cell protein, precision-fermented animal protein (whey beta-lactoglobulin from Perfect Day, ovalbumin from EVERY Co., others), and cultured meat remain in various stages of AAFCO review as of 2024.
Why it was recalled
The structural concerns have three layers. Layer one — commercial timeline pressure conflicts with regulatory deliberation pace: alternative protein companies typically have venture-funded commercial timelines requiring product market entry within 3-5 years of company formation. The AAFCO IDC novel-ingredient pathway typically requires 5-7 years from petition through Official Publication inclusion. The mismatch produces pressure for companies to enter commercial markets at tentative-definition status (which is permitted but introduces regulatory ambiguity), pursue alternative regulatory pathways (FDA GRAS self-affirmation, FDA food additive petition, FDA-CVM no-questions-letter for ingredient safety), or exit the US market for international markets with faster regulatory frameworks. EU EFSA (European Food Safety Authority) novel food approval typically operates on 18-36 month timelines after complete petition submission, faster than AAFCO IDC. Some insect protein companies have pursued EU market entry first to validate commercial demand before completing US AAFCO approval.
Layer two — tentative-definition status permits commercial use but creates consumer-disclosure ambiguity: ingredients in tentative definition status can legally appear in commercial US pet food sold in states that adopt AAFCO Official Publication through cross-reference. The tentative status indicates the ingredient is under active IDC review and may face definition modification, restriction, or denial before reaching official status. Pet food sold with tentative-status ingredients carries regulatory uncertainty — the ingredient may be permitted today but restricted tomorrow based on IDC review outcome. Consumer-facing pet food marketing rarely discloses tentative-versus-official definition status, even though the underlying regulatory rigor differs meaningfully.
Layer three — alternative regulatory pathways introduce framework fragmentation: some novel ingredients reach commercial pet food through pathways outside the AAFCO IDC process. FDA GRAS (Generally Recognized as Safe) self-affirmation permits ingredient sponsors to self-determine GRAS status with optional FDA notification, providing a faster pathway for ingredients with established safety history in human food. FDA food additive petition provides a formal federal approval pathway but typically requires 3-5 years and significant data investment. FDA-CVM no-questions-letter is an informal federal recognition that an ingredient is not raising safety concerns at the current use level, providing soft federal endorsement without formal AAFCO definition. The framework fragmentation produces a multi-pathway environment where some novel ingredients reach pet food through AAFCO IDC, others through FDA GRAS self-affirmation, others through FDA food additive petition, and others through FDA-CVM no-questions-letters — with different regulatory rigor and consumer-disclosure characteristics.
Health risks for your pet
The novel ingredient approval pathway itself does not directly produce pet health risks; the AAFCO IDC framework with FDA-CVM ex-officio safety review is generally rigorous for ingredients reaching official definition status. Indirect health-impact concerns include: (i) tentative-status ingredient commercial use permits ingredients to enter pet food before completing full IDC review, introducing some residual safety uncertainty — mitigated by FDA-CVM safety review at the preliminary tentative stage; (ii) alternative regulatory pathway use may produce ingredients in commercial pet food that have not undergone AAFCO IDC review at all, with consumer-disclosure transparency around regulatory pathway rarely surfaced at brand level; (iii) tentative-definition modifications mid-commercial may produce ingredient restriction or reformulation requirements, occasionally with retroactive impact on products already in commerce.
For black soldier fly larvae (BSF, the best-documented novel-ingredient AAFCO case), long-term feeding evidence in companion animals remains limited despite official AAFCO definition status. Most companion animal feeding studies are short-duration (4-12 weeks) with limited population sizes, focused on palatability, digestibility, and short-term tolerance rather than long-term health outcomes across full life stages. The framework treats AAFCO official definition status as adequate for commercial use but does not require long-term safety evidence equivalent to therapeutic diet feeding trial substantiation. For pet owners, the practical interpretation is that novel-ingredient pet food has cleared regulatory safety review but carries less long-term evidence than established-ingredient pet food.
What to do if you bought affected product
Pet owners can navigate novel-ingredient pet food meaningfully through several practical approaches: (1) treat novel-ingredient pet food as innovation-tier products — ingredients like black soldier fly larvae, cricket protein, mealworm, microbial single-cell protein, precision-fermented animal protein, and cultured meat represent the leading edge of pet food ingredient innovation; (2) verify AAFCO definition status for novel ingredients in your pet's food — request from brand customer service or reference the current AAFCO Official Publication; official definition status indicates full regulatory rigor, tentative status indicates ongoing IDC review, and absence from AAFCO indicates alternative regulatory pathway (FDA GRAS self-affirmation, FDA food additive petition, FDA-CVM no-questions-letter); (3) watch for tentative-definition modifications through AAFCO Official Publication annual updates and pet food trade press coverage; (4) for pets with no prior alternative protein exposure, introduce novel-ingredient pet food gradually over a 1-2 week transition period — novel protein allergies are uncommon but possible, and gradual introduction minimizes gastrointestinal adjustment; (5) recognize that long-term feeding evidence is typically limited for novel ingredients — even AAFCO-defined ingredients like BSF have not been subject to multi-year cohort feeding studies in companion animals at the rigor level of established protein sources; (6) for pets with chronic enteropathy, kidney disease, or other special conditions, discuss novel-ingredient pet food options with your veterinarian — the long-term evidence gap matters more for special populations than for healthy adult pets; (7) treat the novel-ingredient framework as an opportunity-and-uncertainty space rather than an active concern — alternative protein offers favorable sustainability and feed-conversion characteristics, with the trade-off of less long-term companion-animal feeding evidence than established ingredients.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently distinguish AAFCO official definition status from tentative or alternative-pathway regulatory status per our published methodology, since regulatory pathway is rarely disclosed at brand level and the framework operates upstream of consumer-facing pet food labeling. Future rubric extension under consideration: brands disclosing novel-ingredient regulatory pathway (AAFCO official, tentative, FDA GRAS self-affirmation, FDA food additive, FDA-CVM no-questions-letter) and long-term companion-animal feeding evidence would receive favorable scoring weight as transparency signal. The broader novel-ingredient framework is covered across our black soldier fly larvae, cultured meat, and tranche-14 alternative protein controversy pages. For now, our recommendation: treat novel-ingredient pet food as innovation-tier products with full regulatory clearance but limited long-term feeding evidence, and approach with gradual introduction and veterinary consultation for special populations.